Literature DB >> 27791120

Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.

Leopold Kong1, David E Lee2, Rameshwar U Kadam1, Tong Liu2, Erick Giang3, Travis Nieusma1, Fernando Garces1, Netanel Tzarum1, Virgil L Woods2, Andrew B Ward1, Sheng Li2, Ian A Wilson4,5, Mansun Law6.   

Abstract

Hepatitis C virus (HCV) is a major cause of liver disease, affecting over 2% of the world's population. The HCV envelope glycoproteins E1 and E2 mediate viral entry, with E2 being the main target of neutralizing antibody responses. Structural investigations of E2 have produced templates for vaccine design, including the conserved CD81 receptor-binding site (CD81bs) that is a key target of broadly neutralizing antibodies (bNAbs). Unfortunately, immunization with recombinant E2 and E1E2 rarely elicits sufficient levels of bNAbs for protection. To understand the challenges for eliciting bNAb responses against the CD81bs, we investigated the E2 CD81bs by electron microscopy (EM), hydrogen-deuterium exchange (HDX), molecular dynamics (MD), and calorimetry. By EM, we observed that HCV1, a bNAb recognizing the N-terminal region of the CD81bs, bound a soluble E2 core construct from multiple angles of approach, suggesting components of the CD81bs are flexible. HDX of multiple E2 constructs consistently indicated the entire CD81bs was flexible relative to the rest of the E2 protein, which was further confirmed by MD simulations. However, E2 has a high melting temperature of 84.8 °C, which is more akin to proteins from thermophilic organisms. Thus, recombinant E2 is a highly stable protein overall, but with an exceptionally flexible CD81bs. Such flexibility may promote induction of nonneutralizing antibodies over bNAbs to E2 CD81bs, underscoring the necessity of rigidifying this antigenic region as a target for rational vaccine design.

Entities:  

Keywords:  CD81-binding site; E2; conformational flexibility; hepatitis C virus; protein dynamics

Year:  2016        PMID: 27791120      PMCID: PMC5111675          DOI: 10.1073/pnas.1609780113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  65 in total

1.  EMAN: semiautomated software for high-resolution single-particle reconstructions.

Authors:  S J Ludtke; P R Baldwin; W Chiu
Journal:  J Struct Biol       Date:  1999-12-01       Impact factor: 2.867

2.  Do viral proteins possess unique biophysical features?

Authors:  Nobuhiko Tokuriki; Christopher J Oldfield; Vladimir N Uversky; Igor N Berezovsky; Dan S Tawfik
Journal:  Trends Biochem Sci       Date:  2008-12-04       Impact factor: 13.807

Review 3.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

Review 4.  From non-A, non-B hepatitis to hepatitis C virus cure.

Authors:  Jean-Michel Pawlotsky; Jordan J Feld; Stefan Zeuzem; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

5.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

Review 6.  Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?

Authors:  Christopher M Walker; Arash Grakoui
Journal:  Curr Opin Immunol       Date:  2015-08-01       Impact factor: 7.486

7.  Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Authors:  Annalisa Meola; Alexander W Tarr; Patrick England; Luke W Meredith; C Patrick McClure; Steven K H Foung; Jane A McKeating; Jonathan K Ball; Felix A Rey; Thomas Krey
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

8.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

9.  Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China.

Authors:  Zhihui Zhang; Yufeng Yao; Wenlong Wu; Ruilin Feng; Zhongxiang Wu; Wei Cun; Shaozhong Dong
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  45 in total

1.  Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors.

Authors:  Fernando Aleman; Netanel Tzarum; Leopold Kong; Kenna Nagy; Jiang Zhu; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

2.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Authors:  Andrew I Flyak; Stormy Ruiz; Michelle D Colbert; Tiffany Luong; James E Crowe; Justin R Bailey; Pamela J Bjorkman
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

3.  Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.

Authors:  Madeleine C Mankowski; Valerie J Kinchen; Lisa N Wasilewski; Andrew I Flyak; Stuart C Ray; James E Crowe; Justin R Bailey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-18       Impact factor: 11.205

4.  Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.

Authors:  Fang Chen; Kenna Nagy; Deborah Chavez; Shelby Willis; Ryan McBride; Erick Giang; Andrew Honda; Jens Bukh; Phillip Ordoukhanian; Jiang Zhu; Sharon Frey; Robert Lanford; Mansun Law
Journal:  Gastroenterology       Date:  2019-12-04       Impact factor: 22.682

Review 5.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Authors:  Valerie J Kinchen; Andrea L Cox; Justin R Bailey
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

6.  An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.

Authors:  Kathleen McCaffrey; Irene Boo; Catherine M Owczarek; Matthew P Hardy; Matthew A Perugini; Louis Fabri; Pierre Scotney; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

Review 7.  All-atom virus simulations.

Authors:  Jodi A Hadden; Juan R Perilla
Journal:  Curr Opin Virol       Date:  2018-09-01       Impact factor: 7.090

8.  Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins.

Authors:  Fang Chen; Netanel Tzarum; Xiaohe Lin; Erick Giang; Rodrigo Velázquez-Moctezuma; Elias H Augestad; Kenna Nagy; Linling He; Mayda Hernandez; Mallorie E Fouch; Ariadna Grinyó; Deborah Chavez; Benjamin J Doranz; Jannick Prentoe; Robyn L Stanfield; Robert Lanford; Jens Bukh; Ian A Wilson; Jiang Zhu; Mansun Law
Journal:  Immunity       Date:  2021-03-05       Impact factor: 31.745

9.  Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.

Authors:  Mphatso D Kalemera; Joan Capella-Pujol; Ana Chumbe; Alexander Underwood; Rowena A Bull; Janke Schinkel; Kwinten Sliepen; Joe Grove
Journal:  J Gen Virol       Date:  2021-01       Impact factor: 3.891

10.  Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.

Authors:  Brian G Pierce; Zhen-Yong Keck; Ruixue Wang; Patrick Lau; Kyle Garagusi; Khadija Elkholy; Eric A Toth; Richard A Urbanowicz; Johnathan D Guest; Pragati Agnihotri; Melissa C Kerzic; Alexander Marin; Alexander K Andrianov; Jonathan K Ball; Roy A Mariuzza; Thomas R Fuerst; Steven K H Foung
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.